Trial Profile
Expanded Access to ABT-414
Status:
Suspended
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Depatuxizumab mafodotin (Primary)
- Indications Glioblastoma; Solid tumours
- Focus Expanded access; Therapeutic Use
- Sponsors AbbVie
- 17 May 2019 According to an Abbvie media release, the Phase 3 INTELLANCE-1 study had to be stopped due to the lack of survival benefit. An Independent Data Monitoring Committee (IDMC) recommended the study be stopped. Also, the enrollment in all ongoing Depatux-M studies has been halted.
- 17 May 2019 Status changed from recruiting to suspended, according to an AbbVie media release.
- 24 Apr 2017 New trial record